



NDA 020065/S-033

SUPPLEMENT APPROVAL

Bausch & Lomb Incorporated
Attention: Shaun A. Mbithi
Associate Director, Global Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Ms. Mbithi:

Please refer to your supplemental new drug application (sNDA) dated and received March 25, 2022, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Opcon-A (pheniramine maleate and naphazoline hydrochloride) ophthalmic solution.

This "Prior Approval" supplemental new drug application provides for changes to your labeling and packaging configuration you have made to your NDA product since the last approval of the NDA on July 31, 2007, as requested by FDA in our February 24, 2022, Prior Approval supplement request letter.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling, described in the table below and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

Submitted Draft Labeling	Date Submitted
Opcon-A 15 mL Carton	September 13, 2022
Opcon-A 15 mL Container	September 13, 2022
Opcon-A 2x15 mL Twin Pack Carton	September 13, 2022

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.¹ For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 020065/S-033.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Michael Boblitz, PharmD, Regulatory Project Manager at Michael.Boblitz@fda.hhs.gov or (301) 837-7651.

Sincerely,

{See appended electronic signature page}

Karen Minerve Murry, MD, FACE
Deputy Director, Office of Nonprescription Drugs
Acting Director, Division of Nonprescription Drugs II
Center for Drug Evaluation and Research

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

² <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

ENCLOSURE(S):

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

KAREN M MURRY
09/23/2022 02:29:31 PM